Company profile
Pion Inc.(Uk) Ltd
Pion - Leader in Next-Gen Pharma Development
Unique Instruments and Services that Help Scientists Make Informed Decisions About Food and Drug Formulation from R&D to Manufacturing
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts due
Accounts DueNext accounts due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Accounts With Accounts Type Small
Accounts PDF pendingAA | Transaction MzQzMzYxNTY4OGFkaXF6a2N4 | Paper/PDF filed
Published 01 Sep 2024 06:44
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Evaluation of in-vitro tests to reduce animal testing in drug toxicology studies
1 Jan 2015 to 31 Dec 2015
Tens of thousands of animals are sacrificed every year in the UK during drug toxicity testing; many more worldwide. Toxicity testing is an important part of drug development. Newly discovered molecules are tested, as well as metabolites and new formulations. The tests are generally done on rats, mice and dogs. Many of these tests are not actually done to ...
A New Instrument to Support Drug Formulation
1 Aug 2013 to 30 Jun 2014
Our goal is to build a new instrument that can be used by pharmaceutical scientists to investigate formulations of “small molecule” drugs. The active pharmaceutical ingredients (APIs) in most drugs on the market today are organic compounds with molecular weight of 500 or less which interact with receptors in the human body to produce a desired therapeutic...
An Instrument to Simulate Subcutaneous Injection.
1 Aug 2013 to 31 Jan 2015
We want to build an instrument to simulate what happens at the site of injection when a drug is administered subcutaneously into the human body. The instrument will be used to test newformulations, and to control the quality of manufactured batches of existing products. Many new drugs are biopharmaceuticals, such as proteins or peptides. Due to poor stabi...